Innovative Targeting Solutions Granted U.S. Patent
September 6, 2011
Burnaby, BC – September 6, 2011 ‐ Innovative Targeting Solutions Inc., the developer of the next generation fully human antibody technology (HuTARG), today announced issuance of U.S. patent 8,012,714 B2 covering the core technology.
About Innovative Targeting Solutions Inc.
Founded in 2008, Innovative Targeting Solutions Inc. (ITS) is a privately‐held company discovering novel protein medicines. ITS has developed a next generation platform for the generation of fully human antibody therapeutics. The HuTARG technology is a fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination allowing for tolerance free repertoires.